DrugPatentWatch Database Preview
King Pharms Company Profile
What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?
KING PHARMS has twenty-seven approved drugs.
There are six US patents protecting KING PHARMS drugs.
Summary for King Pharms
| US Patents: | 6 |
| Tradenames: | 25 |
| Ingredients: | 23 |
| NDAs: | 27 |
Drugs and US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-001 | Jan 28, 1991 | AB | RX | Yes | No | 7,368,469 | ➤ Sign Up | ➤ Sign Up | |||
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-004 | Mar 20, 2002 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-007 | May 25, 2001 | AB1,AB3 | RX | Yes | No | 7,067,148 | ➤ Sign Up | Y | ➤ Sign Up | ||
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-001 | Mar 20, 2002 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| King Pharms Llc | PENICILLIN G PROCAINE | penicillin g procaine | INJECTABLE;INJECTION | 060101-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-011 | May 25, 2001 | AB1,AB3 | RX | Yes | Yes | 7,101,569 | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-002 | Mar 20, 2002 | 6,066,339 | ➤ Sign Up |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-002 | Jan 28, 1991 | 4,587,258 | ➤ Sign Up |
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-006 | Dec 18, 2008 | 6,066,339 | ➤ Sign Up |
| King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | 3,777,033 | ➤ Sign Up |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-001 | Jan 28, 1991 | 5,061,722 | ➤ Sign Up |
| King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | 3,975,536 | ➤ Sign Up |
| King Pharms | PROCANBID | procainamide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020545-002 | Jan 31, 1996 | 5,656,296 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for KING PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2004-11-04 |
| ➤ Subscribe | Extended-release Capsules | 45 mg and 75 mg | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg | ➤ Subscribe | 2007-06-04 |
Non-Orange Book US Patents for King Pharms
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,378,434 | Metaxalone products, method of manufacture, and method of use | ➤ Sign Up |
| 6,683,102 | Methods of using metaxalone in the treatment of musculoskeletal conditions | ➤ Sign Up |
| 6,407,128 | Method for increasing the bioavailability of metaxalone | ➤ Sign Up |
| 8,168,664 | Metaxalone products, method of manufacture, and method of use | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for King Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Czech Republic | 300687 | ➤ Sign Up |
| South Korea | 20040100835 | ➤ Sign Up |
| Canada | 2488370 | ➤ Sign Up |
| Bulgaria | 110003 | ➤ Sign Up |
| Croatia | P20020170 | ➤ Sign Up |
| Australia | 2002332507 | ➤ Sign Up |
| Australia | 2005209687 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for King Pharms Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 80030 | Netherlands | ➤ Sign Up | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
| C/GB98/047 | United Kingdom | ➤ Sign Up | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
| 323 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| C0062 | France | ➤ Sign Up | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
| C/GB03/034 | United Kingdom | ➤ Sign Up | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
| C0001 | Belgium | ➤ Sign Up | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
| 13/055 | Ireland | ➤ Sign Up | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
